Detalhe da pesquisa
1.
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
Blood
; 2024 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38493484
2.
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Blood
; 2024 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38687605
3.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 403(10423): 249-260, 2024 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048786
4.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Blood
; 141(17): 2047-2061, 2023 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724453
5.
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Lancet
; 402(10399): 373-385, 2023 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37311468
6.
TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
Cancer
; 129(2): 175-180, 2023 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36397669
7.
A Nationwide Study of GATA2 Deficiency in Italy Reveals Novel Symptoms and Genotype-phenotype Association.
J Clin Immunol
; 43(8): 2192-2207, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37837580
8.
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
N Engl J Med
; 382(2): 140-151, 2020 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31914241
9.
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Ann Hematol
; 102(2): 311-321, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36635381
10.
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2.
Future Oncol
; 19(9): 631-642, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37083373
11.
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
BMC Cancer
; 22(1): 1013, 2022 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36153475
12.
Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies.
Hematol Oncol
; 40(4): 491-504, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35368098
13.
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Cancer
; 127(12): 2015-2024, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33739457
14.
Advances in myelodysplastic syndrome.
Curr Opin Oncol
; 33(6): 681-686, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34474438
15.
How I treat MDS after hypomethylating agent failure.
Blood
; 133(6): 521-529, 2019 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30545832
16.
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
Blood
; 139(4): 624-629, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34758066
17.
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.
Blood
; 140(20): 2170-2174, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35797468
18.
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.
Biol Blood Marrow Transplant
; 24(8): 1754-1758, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29649620
19.
PIEZO1 mutations impact on early clinical manifestations of myelodysplastic syndromes.
Am J Hematol
; 98(4): E72-E75, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36695705
20.
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.
Br J Haematol
; 177(5): 741-750, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28419408